Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease, Mark C. Genovese, Maria Greenwald, et al.
New England Journal of Medicine (2014) Vol. 370, Iss. 24, pp. 2295-2306
Open Access | Times Cited: 377

Showing 1-25 of 377 citing articles:

Psoriatic Arthritis
Christopher T. Ritchlin, Robert A. Colbert, Dafna D. Gladman
New England Journal of Medicine (2017) Vol. 376, Iss. 10, pp. 957-970
Closed Access | Times Cited: 1095
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Laure Gossec, Josef S Smolen, Sofía Ramiro, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 3, pp. 499-510
Open Access | Times Cited: 885
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Michele W.L. Teng, Edward P. Bowman, Joshua McElwee, et al.
Nature Medicine (2015) Vol. 21, Iss. 7, pp. 719-729
Closed Access | Times Cited: 784
Psoriasis
Jacqueline Greb, Ari M. Goldminz, James T. Elder, et al.
Nature Reviews Disease Primers (2016) Vol. 2, Iss. 1
Open Access | Times Cited: 741
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease, Iain B. McInnes, Bruce Kirkham, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 14, pp. 1329-1339
Open Access | Times Cited: 684
Inflammation, Immunity, and Hypertensive End-Organ Damage
William G. McMaster, Annet Kirabo, Meena S. Madhur, et al.
Circulation Research (2015) Vol. 116, Iss. 6, pp. 1022-1033
Open Access | Times Cited: 639
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Clinical Reviews in Allergy & Immunology (2018) Vol. 55, Iss. 3, pp. 379-390
Open Access | Times Cited: 593
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease, Désirée van der Heijde, Christopher T. Ritchlin, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 1, pp. 79-87
Open Access | Times Cited: 502
The pathogenic role of angiogenesis in rheumatoid arthritis
Hatem A. Elshabrawy, Zhenlong Chen, Michael V. Volin, et al.
Angiogenesis (2015) Vol. 18, Iss. 4, pp. 433-448
Open Access | Times Cited: 472
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Dhavalkumar D. Patel, Vijay K. Kuchroo
Immunity (2015) Vol. 43, Iss. 6, pp. 1040-1051
Open Access | Times Cited: 460
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis Care & Research (2018) Vol. 71, Iss. 1, pp. 2-29
Open Access | Times Cited: 438
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 1, pp. 5-32
Open Access | Times Cited: 401
The IL-23–IL-17 axis in inflammatory arthritis
Erik Lubberts
Nature Reviews Rheumatology (2015) Vol. 11, Iss. 7, pp. 415-429
Closed Access | Times Cited: 395
IL-17 in Chronic Inflammation: From Discovery to Targeting
Audrey Beringer, Mélissa Noack, Pierre Miossec
Trends in Molecular Medicine (2016) Vol. 22, Iss. 3, pp. 230-241
Closed Access | Times Cited: 377
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, et al.
The Lancet (2017) Vol. 389, Iss. 10086, pp. 2317-2327
Closed Access | Times Cited: 357
Interleukin-17 and innate immunity in infections and chronic inflammation
Natasa Isailovic, Kenji Daigo, Alberto Mantovani, et al.
Journal of Autoimmunity (2015) Vol. 60, pp. 1-11
Closed Access | Times Cited: 346
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
Stephan R. Targan, Brian G. Feagan, Séverine Vermeire, et al.
The American Journal of Gastroenterology (2016) Vol. 111, Iss. 11, pp. 1599-1607
Closed Access | Times Cited: 328
Psoriasis: Which therapy for which patient
Shivani B. Kaushik, Mark Lebwohl
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 27-40
Closed Access | Times Cited: 322
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Stefan Siebert, Alexander Tsoukas, Jamie Robertson, et al.
Pharmacological Reviews (2015) Vol. 67, Iss. 2, pp. 280-309
Open Access | Times Cited: 297
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, et al.
Annals of the Rheumatic Diseases (2016) Vol. 75, Iss. 6, pp. 1065-1073
Open Access | Times Cited: 261
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
Ditte Marie Lindhardt Saunte, Ulrich Mrowietz, L. Puig, et al.
British Journal of Dermatology (2016) Vol. 177, Iss. 1, pp. 47-62
Closed Access | Times Cited: 241
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies
Judy H. Cho, M Feldman
Nature Medicine (2015) Vol. 21, Iss. 7, pp. 730-738
Open Access | Times Cited: 224
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt, Dominique Baeten, Terry Baker, et al.
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 4, pp. 523-532
Open Access | Times Cited: 220
The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases
Jacek Tabarkiewicz, Katarzyna Pogoda, Agnieszka Karczmarczyk, et al.
Archivum Immunologiae et Therapiae Experimentalis (2015) Vol. 63, Iss. 6, pp. 435-449
Open Access | Times Cited: 219
Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity
Patrick R. Burkett, Gerd Meyer zu Hörste, Vijay K. Kuchroo
Journal of Clinical Investigation (2015) Vol. 125, Iss. 6, pp. 2211-2219
Open Access | Times Cited: 212
Page 1 - Next Page

Scroll to top